| Similar Articles |
|---|
 |
Chemistry World
August 29, 2013
Emma Stoye |
Couple charged in GSK corruption investigation A UK consultant and his American wife have been charged in relation to the corruption investigation at GlaxoSmithKline in China.   |
Chemistry World
July 12, 2013
Phillip Broadwith |
GSK under investigation over corruption in China Chinese police are investigating GlaxoSmithKline over claims of bribery and tax-related crimes. |
Chemistry World
August 6, 2014
Hepeng Jia |
GSK's China troubles continue The company faces official prosecution over accusations of bribery and corruption, litigation from fired employees and an upcoming trial of private investigators employed to look into a blackmail attempt. |
Chemistry World
May 14, 2014
Phillip Broadwith |
Chinese police hand GSK bribery case to prosecutors The Chinese state news agency Xinhua has released details of the police investigation, claiming that 46 suspects are involved including Mark Reilly, former manager of GSK China. |
Chemistry World
July 29, 2013
Hepeng Jia |
China corruption investigation broadens Investigations of corrupt practices at GlaxoSmithKline in China are continuing. But analysts claim that the scandal is an attempt to remodel the Chinese drugs market, rather than a deliberate attack on international companies. |
Chemistry World
September 25, 2014
Hepeng Jia |
GSK fined 300 million for China corruption After investigation by Chinese police, the British pharmaceutical giant GlaxoSmithKline was fined a record Yuan3 billion ( 300 million pounds) for bribing Chinese doctors and hospital officials. |
Chemistry World
April 23, 2014
Phillip Broadwith |
GSK corruption investigation widens Pharma giant GlaxoSmithKline has responded to allegations made by the BBC's Panorama program concerning improper conduct by GSK's sales staff in Poland. |
Chemistry World
June 10, 2014
Anthony King |
Drug giants settle mismarketing lawsuits Pfizer and GlaxoSmithKline recently agreed to separate settlements over allegations of mismarketing drugs in the US. |
Pharmaceutical Executive
August 1, 2005
Lena Chow |
Docs of Shanghai They're short on status, pay, and respect, but China's young doctors hold keys to the world's fastest growing pharmaceutical market. |
BusinessWeek
April 23, 2009
Catherine Arnst |
Doctors' Pride: A Hurdle to Digital Medicine A forerunner in New England found that some physicians would sooner cut ties than see their elite status threatened. |
The Motley Fool
October 26, 2011
Brian Orelli |
Down 20%: Benylsta Not Ramping Fast Enough Sales of Human Genome Sciences' new lupus drug Benylsta continues to grow -- just not fast enough to keep investors interest. |
Managed Care
July 2000
John Carroll |
Physicians Reconsider Taking On Pharmacy Risk They've been burned here in the past, but physicians - and the HMOs that they contract with - may have learned some lessons. |
The Motley Fool
January 8, 2008
Brian Orelli |
A Painful Reminder From the FDA The agency issues a reminder that osteoporosis drugs can cause severe pain. |
The Motley Fool
September 15, 2011
Frank Vinluan |
GSK's New Drug Marketing Model: Pharma Reps As Educators, Not Sellers The conversation between sales reps and doctors today is vastly different compared to one year ago. |
Chemistry World
November 28, 2012
Andrew Turley |
GSK expands in India and Nigeria GlaxoSmithKline is to spend 650 million pounds dramatically increasing its ownership of Indian and Nigerian subsidiaries. |
Pharmaceutical Executive
August 1, 2013
William Looney |
One Company -- One Moment The trade media is ablaze with lurid accounts of bribery, tax fraud, and other illicit promotional activities in China -- ironically, the country touted as guarantor of our industry's future. |
The Motley Fool
January 8, 2004
Rich Smith |
Oops, I(BM) Did it Again Once again IBM finds itself embattled in bribing controversy abroad. |
Chemistry World
September 24, 2010
Andrew Turley |
End of the road for Avandia? The European Medicines Agency has decided the troubled diabetes drug should be pulled from the market while the US Food and Drug Administration has said it will 'significantly restrict' its use. |
Chemistry World
April 19, 2013
Phillip Broadwith |
Objections raised to GSK pay-for-delay deals The UK Office of Fair Trading has said that GlaxoSmithKline's deals to delay generic drugs infringed competition laws. |
Pharmaceutical Executive
September 1, 2006
Patrick Clinton |
From the Editor: Undecided People are buying drugs, because companies are selling drugs. Interfere with the selling process, and people won't buy as many drugs. |
The Motley Fool
December 4, 2007
Brian Orelli |
An Early Gift to Drugmakers Drugmakers could be allowed to market for drugs' off-label indications. |
Chemistry World
January 30, 2007
Bea Perks |
BBC and GSK Battle Over Seroxat The UK pharmaceutical giant, which has spent the past few years fighting off accusations of risks associated with its market-leading anti-depressant, has rejected fresh claims that it improperly withheld medical trial information in the 1990s. |
The Motley Fool
September 25, 2008
Brian Lawler |
Eli Lilly's Dose of Disclosure The pharmaceutical pledges public reports of its dealings with doctors. |
CIO
December 15, 2009
Kim S. Nash |
Data Sharing That Benefits Customers At Children's Hospital Boston, sharing more data, securely, promises healthier, more satisfied patients. |
CIO
August 1, 2002
Stephanie Overby |
Rx for Chicken Scratch Poor physician penmanship is the butt of many jokes, but illegible prescriptions are no laughing matter. Some pharmacies are starting to use electronic systems to accept prescriptions from doctors electronically via PC, PDA, or cell phone, thus ensuring accurate prescription filling. |
Chemistry World
July 2, 2012
Andrew Turley |
$3bn GSK fine sets new industry record The GlaxoSmithKline fine, which relates to antidepressant brands Paxil (paroxetine) and Wellbutrin (bupropion) and diabetes brand Avandia (rosiglitazone), is the largest payment ever made by a drug company. |
Pharmaceutical Executive
March 1, 2006
Dorfman & Maynor |
Marketing to Professionals: Under the Influence Pharmaceutical marketers should target the doctors who affect change in the medical community. |
BusinessWeek
November 20, 2008 |
Financial Triage Innovative ways that hospitals are looking at patient finances. |
Chemistry World
May 19, 2015
Phillip Broadwith |
GSK commits to HIV research GlaxoSmithKline has reaffirmed its commitment to researching new drugs for HIV -- Aids, by partnering with the University of North Carolina in Chapel Hill, US. |
Chemistry World
September 17, 2013
Phillip Broadwith |
GSK criticized for trial data secrecy An Italian research institute has withdrawn from a public -- private partnership after quarrelling with GlaxoSmithKline about access to data from an antibiotic clinical trial being run by the institute. |
Chemistry World
April 25, 2014
Andy Extance |
$25bn-plus trade sharpens pharma giants' focus Three leading pharmaceutical firms are set to exchange business segments valued at over $25 billion, in deals affecting at least 14,000 employees. |
The Motley Fool
July 26, 2011
Cliff D'Arcy |
GSK Showers Shareholders With Cash GlaxoSmithKline, the U.K.'s largest pharmaceutical company, has released its second-quarter results. Thanks to rising earnings and dividends, its shares remain attractively priced, particularly to income-seeking investors. |
Chemistry World
January 4, 2011
Andrew Turley |
Funding pharma whistleblowers Hedge fund managers say that US whistleblower lawsuits filed against drug companies could provide attractive investment opportunities. |
Chemistry World
September 30, 2014 |
Transparency measures forced on pharma Previous misdemeanors are compelling the pharmaceutical industry to be more open with financial information and clinical data. |
InternetNews
November 11, 2010 |
HP, DoJ Reach Settlement in E-Rate Fraud Case HP has agreed to pay $16.25 million to resolve allegations that former employees and contractors defrauded the federal telecom subsidy for broadband in schools. |
Chemistry World
February 26, 2010
Sarah Houlton |
Report hits out at GSK's Avandia GlaxoSmithKline's diabetes drug Avandia (rosiglitazone) has been dealt another blow, with the publication of a report by two US senators claiming the company knew about safety problems long before they reached the public domain. |
BusinessWeek
October 4, 2004
Kerry Capell |
Why Glaxo Can't Shake the Flu Sales are weakening as hot sellers come off-patent. But the pipeline looks healthy. And there's the rub. Just when GSK's image is at a new low, its prospects are improving. |
Job Journal
November 28, 2004
Rich Heintz |
Medical Careers: The Rx for Offshoring Looking for a career no one (as yet) can outsource overseas? Consider a position in healthcare. Here are three examples -- medical careers critical to the care of an aging population. |
The Motley Fool
June 14, 2007
Brian Lawler |
Dueling Fools: GlaxoSmithKline Bull Rebuttal Investors who think this pharma's market cap is too large would be missing out on the chance to own one of the best-run companies in the most exciting industry. |
Pharmaceutical Executive
April 1, 2007
Humphrey Taylor |
Opinion: Inappropriate Behavior Do doctors prescribe needless care? Will healthcare costs drop if patients decide whether treatment is necessary? It's time to start talking. |
Managed Care
August 2000 |
Internet revolution not yet impressing most physicians For all the potential of the Internet to erase old physician doubts about integrating information technology into everyday practice, scant few doctors have embraced it. |
The Motley Fool
January 19, 2011
Cliff D'Arcy |
Glaxo Stung by Legal Bill GSK shareholders are hit by costly legal settlements. |
The Motley Fool
June 14, 2007
Brian Lawler |
Dueling Fools: GlaxoSmithKline Bull Shares of the pharmaceutical may be temporarily down, but it's not out. |
Pharmaceutical Executive
February 1, 2007
Humphrey Taylor |
Opinion: Myth vs. Reality The debate about reform of the American healthcare system has been ideologically driven rather than evidence-based. Here, we separate myth from reality. |
The Motley Fool
November 3, 2011
Frank Vinluan |
GSK Settles With Uncle Sam for $3B GSK said the settlement will reduce financial uncertainty for the company and is in the best interest of shareholders. |
The Motley Fool
August 24, 2007
Brian Lawler |
Flamel Under Fire Stocks fall when study fails to show drug's superiority. Investors, take note. |
Entrepreneur
September 2004
Jane Easter Bahls |
Illicit Affairs? If you do business overseas, be certain your "administrative fees" aren't really illegal bribes. And because complying with the many overlapping laws is tricky, hire a lawyer with experience in international business. |
InternetNews
August 3, 2007
Roy Mark |
Online Pill Pushers Busted Doctors, pharmacists and credit-card processor all named in wide-ranging indictment. |
The Motley Fool
September 8, 2008
Rich Duprey |
The Coming Great Pharma Panic The FDA's drug warning list provides dangerously little information. |
Chemistry World
December 5, 2014
Andy Extance |
GSK cuts US jobs in push for savings 350 of the chemists, engineers and other roles will be lost by April 2015, another 450 by July, and the remainder eliminated by the end of the year. |
